Price (delayed)
$1.22
Market cap
$54.73M
P/E Ratio
4.52
Dividend/share
N/A
EPS
$0.27
Enterprise value
-$42.7M
AVROBIO's vision is to bring personalized gene therapy to the world. The company aims to prevent, halt or reverse disease throughout the body with a single dose of gene therapy
There are no recent dividends present for AVRO.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.